Array Biopharma Inc. (ARRY) Loss Submission Form

Levi & Korsinsky, LLP announces it filed a class action complaint in the USDC for the District of Colorado on behalf of shareholders of Array Biopharma Inc. (NASDAQ: ARRY) who purchased shares between December 16, 2015 and March 17, 2017.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; (2) it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutant melanoma; and (3) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.

On March 19, 2017, Array issued a press release announcing withdrawal of the binimetinib NDA in use for patients with NRAS-mutant melanoma. On May 10, 2017, during a conference call to discuss the Company’s financial and operating results for the third fiscal quarter ended March 31, 2017, Array’s CEO Ron Squarer stated that Array lacked sufficient data to support approval of the NDA.

If you suffered a loss in Array you have until January 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.